Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
361-380 of 991 trials

Cannabidiol for Refractory Childhood Epilepsy

We are studying whether adding CBD can help children with hard-to-treat epilepsy manage their seizures better. The trial also looks at how this treatment affects the quality of life for patients and their families.

Refractory Epilepsy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Immunoglobulin A Nephropathy: Ravulizumab Study

We are testing whether ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy. The study will also assess safety and quality of life compared to a placebo.

Immunoglobulin A Nephropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Ulcerative Colitis: Eltrekibart Treatment Study

We are studying whether eltrekibart can help adults with moderately to severely active ulcerative colitis achieve remission. This trial compares the effects of eltrekibart to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Severe Systemic Lupus Erythematosus: Belimumab and Rituximab Study

We are investigating whether combining belimumab with rituximab can improve treatment outcomes for people with severe systemic lupus erythematosus. This study will compare this combination to standard treatments to see if it better reduces harmful autoantibodies and improves overall health.

Systemic Lupus Erythematosus>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

ANCA-Associated Vasculitis: Rituximab with Cyclophosphamide

We are studying the effects of combining rituximab with cyclophosphamide compared to rituximab alone in patients with ANCA-associated vasculitis. This research aims to find out how these treatments help maintain remission and their impact on patient health.

ANCA Vasculitis>2 yearsMonitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementRheumatology

Multiple Myeloma: Elranatamab vs. Standard Treatments

We are studying a new treatment called elranatamab for people with relapsed refractory multiple myeloma. The goal is to see how well it works compared to current therapies and to assess its safety and impact on quality of life.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Mpox Vaccination Study: MPOX-VAX

We are studying a vaccine to see how well it prevents Mpox infection and how long the immune response lasts. Participants will also be monitored for other infections to understand overall health impacts.

Mpox Infection6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Systemic Juvenile Idiopathic Arthritis: Baricitinib Study

We are studying the effectiveness of baricitinib in children aged 1 to under 18 with systemic juvenile idiopathic arthritis. This research aims to find out if it helps improve their condition.

Systemic Juvenile Idiopathic Arthritis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Ovarian Cancer: Raludotatug Deruxtecan Study

We are studying a new drug for patients with platinum-resistant, high-grade ovarian cancer. The goal is to see if it works better than current treatment options.

Ovarian and Related Cancers>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Scabies Treatment: Comparing Permethrin Creams

We are testing whether a new 10% permethrin cream works better than the standard 5% cream for treating scabies. We will also look at the safety of the new cream.

Scabies>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious Diseases

Methylphenidate for Cancer-Related Fatigue in Young Brain Tumor Survivors

We are studying whether methylphenidate can help reduce fatigue in patients who were treated for brain tumors during childhood or adolescence. Additionally, we will look at its effects on sleep, cognitive function, and quality of life.

Cancer-related Fatigue after Pediatric Brain Tumor Treatment3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementOncologyPediatrics

Quizartinib for Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

We are studying whether quizartinib, combined with chemotherapy, can improve survival in adults with newly diagnosed FLT3-ITD negative AML compared to a placebo. This trial aims to assess its effectiveness and safety.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementOncology

Advanced Solid Tumors: First-in-Human Study of DS-3939a

We are testing a new treatment called DS-3939a to see if it is safe and effective for people with advanced solid tumors. This study aims to understand how well it works and its effects on tumor tissue.

Metastatic Solid TumorAdvanced Solid TumorSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Biliary Tract Cancers: [18F]F-FAPI PET-CT Imaging Study

We are investigating how a new imaging technique may improve diagnosis and treatment planning for patients with potentially resectable biliary tract cancers. This study will also look at the cost-effectiveness and safety of this imaging method.

Cholangiocarcinoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Pompe Disease: Enzyme Replacement Therapy Study

We are examining how a new enzyme replacement therapy affects muscle glycogen in people with Pompe disease who have not yet received treatment. This research may help improve future therapies for this condition.

Pompe's Disease>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyHematologyNeurology

Chronic Lymphocytic Leukemia: Lisaftoclax Treatment Study

We are studying whether a new drug, lisaftoclax, combined with another treatment, helps patients with chronic lymphocytic leukemia who have been previously treated. The goal is to see if this combination improves survival and slows disease progression.

Chronic Lymphocytic Leukemia (CLL) / Small Cell Lymphocytic Lymphoma (SLL)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Ovarian Cancer: Sacituzumab Tirumotecan Study

We are testing a new treatment for people with recurrent ovarian cancer to see if it works better than standard care. This study looks at safety, tolerability, and how it affects patients' quality of life.

Recurrent Ovarian CancerConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Endometrial Cancer: New Treatment Combinations

We are studying whether a new combination of Trastuzumab Deruxtecan with Rilvegostomig or Pembrolizumab is more effective than standard chemotherapy for patients with advanced or recurrent HER2-expressing endometrial cancer.

Endometrial CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Biliary Tract Cancer: T-DXd and Rilvegostomig Study

We are studying a new treatment combination for patients with advanced HER2-expressing biliary tract cancer. The goal is to see if it helps improve survival compared to standard care options.

Advanced HER2-expressing Biliary Tract Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Polymyalgia Rheumatica: Secukinumab Safety Study

We are evaluating the long-term safety of secukinumab for individuals with polymyalgia rheumatica. This study will help us understand any potential side effects associated with this treatment.

Polymyalgia Rheumatica>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology